SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : After Glaxo's genital herpes vaccine flop, check out Agenus -- Ignore unavailable to you. Want to Upgrade?


To: robert b furman who wrote (1)10/22/2014 7:44:23 AM
From: robert b furman  Respond to of 22
 
Q 3 earnings just announced.

A beat on earnings yet a 3$ revenue decline.

gsk.com

Up in premarket 1.18.

Confirmed commitment to maintian dividend at 80 pence in 2014 and 2015.

Growth in emerging markets and slower in Europe and USA.

Trying to have a vaccine by next year for ebola with the acclerated help from WHO and trials.

Seems like a good dividend payer with typical pharma growth and new product issues.